JLJ648 is a Gag-Pol dimerizer with antiviral activity. JLJ648 can inhibit HIV replication and induce infected cell pyroptosis. JLJ648 can be used for the research of infection, such as HIV (human immunodeficiency virus).

(R,R)-Abacavir is the (R,R)-enantiomer of Abacavir. Abacavir is an orally active and competitive nucleoside reverse transcriptase inhibitor. Abacavir can inhibits the replication of HIV. Abacavir shows anticancer activity in prostate cancer cell lines. Abacavir can trespass the blood-brain-barrier and suppresses telomerase activity.

DPC 684 is a potent and selective HIV-1 protease inhibitor (IC90 = 5.7-40 nM, Ki = 0.021 nM). DPC 684 competitively inhibits HIV-1 protease and blocks viral polyprotein cleavage. DPC 684 has low protein binding and broad-spectrum inhibition against a variety of wild-type and mutant HIV-1 proteases. DPC 684 has low protein binding and broad-spectrum inhibition (IC90 = 1.9-6.3 nM). DPC 684 has research significance for HIV.

3′-Azido-2′,3′-dideoxy-CTP (AZddCTP) is a cytidine analog containing a 3-azido group. As a chain terminator, 3′-Azido-2′,3′-dideoxy-CTP can be incorporated into the nascent DNA chain by HIV reverse transcriptase. 3′-Azido-2′,3′-dideoxy-CTP terminates DNA synthesis due to the lack of a 3'-hydroxyl group, thereby inhibiting viral replication. 3′-Azido-2′,3′-dideoxy-CTP has IC50 values of 15.6 μM and 160.8 μM for WT HIV and AZTR HIV. 3′-Azido-2′,3′-dideoxy-CTP has antiviral activity.

BMS-663749 is an HIV attachment inhibitor and phosphonooxymethyl prodrug of BMS-488043.

BEA 005 is an antivirus agent. BEA 005 can block early systemic and mucosal infections with SIV and HIV-2.

Lepetegravir (Example 24) is a HIV integrase inhibitor. Lepetegravir has antiviral effects (EC50: 0.98 nM in MT-4 cells).

SB 204144 is an HIV protease inhibitor. SB 204144 can be used in research on immune system diseases.

RM-5038 is a thiazolide antivirus agent. RM-5038 can induce innate immunity and reduce HIV replication.

Rp-TTPαS (tetrasodium) is the Rp-isomer of TTPαS (tetrasodium). Rp-TTPαS (tetrasodium) incorporate with HIV-1 reverse transcriptase (HIV-1 RT) with HIV-1 RT with large phosphorothioate elemental effects.

Sp-TTPαS tetrasodium is a competitivesterile alpha motif and HD domain containing protein 1 (SAMHD1) hydrolysis inhibitor. Sp-TTPαS tetrasodium competitively inhibits SAMHD1 triphosphohydrolase activity with a Ki value of 46 µM.

Mozenavir (DMP 450) is an orally active and highly selective inhibitor of HIV-1 protease (Ki=0.3 nM). Mozenavir blocks the cleavage and processing of viral polyproteins, inhibiting the replication and maturation of HIV-1. Mozenavir is promising for research of HIV infection.

Nef ligand-1 is the Nef binding part of FC-14367.

Lenacapavir pacfosacil (Example 44) is a viral capsid and nucleocapsid inhibitor. Lenacapavir pacfosacil has antiviral effects. Lenacapavir pacfosacil can be used for research of Retroviridae infection, including an HIV infection.

TEI-2306 is a precursor of glutathione biosynthesis. TEI-2306 possesses a unique anti-HIV-1 activity in both chronically and acutely infected cells, and even for free viruses. TEI-2306 can be used for the study of myocardial ischaemia.

PD 161374 is an inhibitor targeting the HIV-1 nucleocapsid protein NCp7. PD 161374 primarily acts on the early stages of viral replication, inhibiting the completion of reverse transcription without affecting viral entry or later assembly. PD 161374 remains active against HIV-1, HIV-2, SIV, and drug-resistant strains. PD 161374 can be used to study antiretroviral agents.

L-738872 is an orally active HIV-l encoded protease inhibitor. L-738872 inhibits the spread of HIV-1 in infected cells.

CGP-75355 is an inhibitor of HIV-1 protease with IC50 of 26 nM. CGP-75355 is a bis(L-tert-leucine) derivative.

KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections.

(±)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (±)-PM 92131 has an anti-HIV-1 activity with IC50s of 45.7 and 53.8 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (±)-PM 92131 can be used for HIV infections research.

Asuptegravir (Compound 1) is an inhibitor of HIV integrase activity. Asuptegravir inhibits HIV in HEK293T cells (EC50 = 1.08 nM). Asuptegravir can be studied in anti-AIDs/HIV research.

(+)-PM 92131 is the active enantiomer of (±)-PM 92131. (+)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (+)-PM 92131 has an anti-HIV-1 activity with EC50s of 0.8 and 0.6 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (+)-PM 92131 can be used for HIV infections research.

Zintevir is an antisense oligonucleotide that targets HIV-1 integrase.

Zintevir sodium is an antisense oligonucleotide that targets HIV-1 integrase.

Peginterferon alfa-2b (PegIFN a-2b) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG. Peginterferon alfa-2b in decreasing viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C.

GPI2A is a 20-mer antisense oligonucleotide sequence that is complementary to a region of the HIV-1 gag gene. GPI2A shows a significant inhibitory effect on p55 and its cleavage product p39/41.

GPI2A sodium is a 20-mer antisense oligonucleotide sequence that is complementary to a region of the HIV-1 gag gene. GPI2A shows a significant inhibitory effect on p55 and its cleavage product p39/41.

148.1-38m sodium, an RNA aptamer, inhibits HIV-1 reverse transcriptase (RT) and interfere with viral replication.

Lenacapavir (GS-6207) sodium is a HIV-1 capsid inhibitor. Lenacapavir sodium shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. Lenacapavir sodium displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).

GSK-364735 sodium (S/GSK-364735 sodium) is the sodium salt form of GSK-364735 that inhibits 5-lipoxygenase with an IC50 value of 26 μM. 15(S)-HEDE is promising for research of inflammatory disease.